Association of Interleukin-27 rs 153109 Single Nucleotide Polymorphism with Spontaneous Resolution of Hepatitis C Virus - Genotype 4a Infection in Egyptian Patients

  • Fawzy, Mariam M (Department of Biochemistry, Faculty of Pharmacy, Minia University) ;
  • Wahid, Ahmed (Department of Biochemistry, Faculty of Pharmacy, Minia University) ;
  • Nazmy, Maiiada H (Department of Biochemistry, Faculty of Pharmacy, Minia University) ;
  • Hashem, Mohamed (Department of Epidemiology and Public Health, University of Maryland School of Medicine) ;
  • Waked, Imam (Hepatology Department, National Liver Institute, Menoufiya University) ;
  • Abdelwahab, Sayed F (Department of Microbiology and Immunology, Faculty of Medicine, Minia University)
  • Published : 2016.06.01


Background: HCV is a major global health problem. IL-27 is a member of the IL-6/IL-12 cytokine family with a broad range of anti-inflammatory properties. Recent studies highlighted the effect of a SNP in the IL-27 promoter region on modulating the progression of infectious diseases and individual responses to therapy. Aim of the work: The present study investigated the potential role of (-964 A/G) SNP in the promoter region of IL-27p28 gene (alleles rs153109) on the outcome of HCV infection among genotype 4a infected patients. Materials and Methods: HCV genotyping confirmed that all of the HCV-infected patients had genotype 4a infection. Genomic DNA was extracted from 111 patients with chronic HCV infection, 42 spontaneous resolvers (SR) and 16 healthy controls. IL- 27p28.rs153109 genotyping was assessed using PCR-RFLP then confirmed by DNA sequencing. Results: The frequency of IL-27-p28.rs153109AA, AG, and GG genotypes among chronically infected subjects were 74.8 %, 25.2%, and 0% while among the SR, they were 57.1%, 35.7%, and 7.14%, respectively. Our data show the unique presence of G/G genotype in the SR group (3 patients; 7.14%). Moreover, the "G" allele frequencies among chronic and resolved subjects were 12.6% and 25.0%, respectively (p=0.0136). Importantly, subjects with the GG genotype were more likely to clear their HCV infection than those with the AA genotype (p=0.0118). Conclusions: HCV genotype 4a subjects with the IL-27-p28.rs153109 A/G and G/G genotype were more likely to clear their HCV infection. Therefore, we propose IL- 27p28.rs153109SNPas a genetic biomarker for predicting HCV infection outcome.


  1. Baldo V, et al (2008). Epidemiology of HCV infection. Curr Pharm Des, 12, 1646-54.
  2. Parkin DM (2000). Global cancer statistics in the year. Lancet Oncol, 2, 533-43.
  3. Badia-Martinez D (2012).Three-dimensional visualization of forming Hepatitis C virus-like particles by electrontomography. Virol, 430, 120-6.
  4. Chen SL, Morgan TR (2006). The natural history of hepatitis C virus (HCV) infection. Int J Med Sci, 3, 47-52.
  5. Wahid A and Dubuisson J (2013). Virus-neutralizing antibodies to hepatitis C virus. J Viral Hepat, 20, 369-76.
  6. Koziel MJ (2005). Cellular immune responses against hepatitis C virus. Clin Infect Dis, 41, 25-31.
  7. Pflanz S (2002). IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity, 16, 779-90.
  8. Sprecher C.A, et al (1998). Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun, 246, 82-90.
  9. Morishima N, et al (2010). A pivotal role for interleukin-27 in CD8+ T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol, 2010, 605483.
  10. Pflanz S (2004). WSX-1 and glycoprotein 130 constitute a signaltransducing receptor for IL-27. J Immunol, 172, 2225-31.
  11. Kastelein RA, Hunter CA, Cua DJ (2007). Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol, 25, 221-42.
  12. Ihle J.N (2001). The Stat family in cytokine signaling. Curr Opin Cell Biol, 13, 211-7.
  13. Takeda A (2003). Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol, 170, 4886-90.
  14. Sonobe Y (2005). Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations. Brain Res, 1040, 202-7.
  15. Ryan E.J, Farrelly C. O’ (2011). The affect of chronic hepatitis C infection on dendritic cell function: a summary of the experimental evidence. J Viral Hepat, 18, 601-7.
  16. Hunter CA (2005). New IL-12-family members: IL-23 and IL- 27, cytokines with divergent functions. Nat Rev Immunol, 5, 521-31.
  17. Frank A.C (2010). Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J Interferon Cytokine Res, 30, 427-31.
  18. Tang T.J (2003). The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat, 10, 159-67.
  19. Imamichi T (2008). IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. AIDS, 22, 39-45.
  20. Fakruddin J.M (2007). Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood, 109, 1841-9.
  21. Liu L (2012). Influenza A virus induces interleukin-27 through cyclooxygenase-2 and protein kinase A signaling. J Biol Chem, 287, 11899-910.
  22. Peng Q, et al (2013). Association of IL27 gene polymorphisms and HBV-related hepatocellular carcinoma risk in a Chinese population. Infect Genet Evol, 16, 1-4.
  23. Yasser B.M, Ali a, et al (2014). Association of Interleukin 27 gene polymorphism and risk of Hepatitis B viral infection in Egyptian population. Egyptian J Medical Human Genetics, 15, 53-59.
  24. Zicca E, et al (2014). Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy? BMC Infect Dis, 14 ,S5.
  25. Knapp S, et al (2011). A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterol, 141, 320-5.
  26. Abdelwahab SF (2015). Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection. Arch Virol, 160, 2833-7.
  27. Sharafi H (2014).The impact of IFNL4 rs12979860 polymorphism on spontaneous clearance of hepatitis C; a case-control study. Hepat Mon, 14, e22649.
  28. Sun H, Pan Y, Wu R, et al (2015). CD24 Ala57Val polymorphismis associated with spontaneous viralclearance in the HCVinfected Chinese population. Liver Int, 35, 786-94.
  29. Ohno O (1997). New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol, 35, 201-7.
  30. Yasser B.M.A, et al (2014). Association of Interleukin 27 gene polymorphism and risk of Hepatitis B viral infection in Egyptian population. Egyptian J Medical Human Genetics, 15, 53-59.
  31. Batten M, Ghilardi N (2007). The biology and therapeutic potential of interleukin 27. J Mol Med (Berl), 85, 661-72.
  32. Komatsu H, et al (2014). Association between single-nucleotide polymorphisms and early spontaneous hepatitis B virus e antigen seroconversion in children. BMC Res Notes, 7, 789.
  33. Chae SC (2007). Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. J Hum Genet, 52, 355-61.
  34. Li CS (2009). Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean population. J Gastroenterol Hepatol, 24, 1692-6.
  35. Xu X.P (2014). Genetic association between IL-27 rs153109 polymorphism and cancer risk in Chinese population: a meta-analysis. J Recept Signal Transduct Res, 1-6.
  36. Huang ZQ (2012). Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk. Clin Biochem, 45, 54-9.
  37. Kruglyak L (1997).The use of a genetic map of biallelic markers in linkage studies. Nat Genet, 17, 21-4.
  38. Schafer AJ, Hawkins JR (1998). DNA variation and the future of human genetics. Nat Biotechnol, 16, 33-9.

Cited by

  1. (rs1800629) Genetic Polymorphisms on the Progression of HCV Infection in Egyptian Patients pp.1532-4311, 2018,